Effects of Infliximab Combined with Mesalazine on Inflammatory Factors,Colonic Mucosal Barrier Indexes and Inflammation-Related Proteins in Patients with Ulcerative Colitis
Objective:To investigate the effects of infliximab combined with mesalazine on inflammatory factors,colonic mucosal barrier indexes and inflammation-related proteins in patients with ulcerative colitis(UC).Methods:A total of 84 patients with UC treated in a hospital from August 2021 to October 2023 were selected and assigned to the control group and observation group by random number table method,with 42 patients in each group.Both groups were given conventional treatment such as fluid rehydration and nutritional support.The control group was given mesalazine enteric coated tablets on the basis of conventional treatment,and the observation group with infliximab for injection in addition to the treatment given in the control group.Inflammatory factors[interleukin-6(IL-6),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)],colonic mucosal barrier indexes[diamine oxidase(DAO),D-lactate],inflammation-related proteins[fecal calprotectin(FC),GATA binding protein 3(GATA-3)],clinical response and adverse reactions were compared between the two groups.Results:After treatment,the serum levels of IL-6,CRP and TNF-α were decreased in both groups(P<0.05),and were lower in the observation group as compared with the control group(P<0.05).The serum levels of DAO and D-lactate were decreased in both groups(P<0.05),and were lower in the observation group as compared with the control group(P<0.05).The levels of FC and serum GATA-3 were decreased in both groups(P<0.05),and were lower in the observation group as compared with the control group(P<0.05).The total response rate in the observation group(85.71%)was higher than that in the control group(61.90%,P<0.05).There was no statistically significant difference in the total incidence of adverse reactions including rash,dizziness,nausea and vomiting between the two groups(P>0.05).Conclusion:Infliximab combined with mesalazine for UC has good clinical efficacy as it can effectively inhibit inflammatory factors,enhance colonic mucosal barrier function,and improve FC and serum GATA-3 levels,without additional risks of adverse reactions.
万方数据
维普
